At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 37 enrolled
Drug / intervention
Cimzia +1 moredrug
Likely dose
Cimzia 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response By Switching to Certolizumab Pegol (Cimzia)? A Phase IV, Randomized, Multi-Center, Double-Blind, Twelve-Week Study Followed by a 12-Week Open-Label Phase
In Brief
A Phase 4 clinical trial evaluating Cimzia and Placebo for Rheumatoid Arthritis. Completed, enrolled 37 participants across 12 sites.
Detailed Summary
Purpose of the study is to determine if Cimzia is safe and effective in subjects who have received previous treatment with a TNF-alpha inhibitor other than Cimzia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
CollaboratorsUCB Pharma
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2010
Enrollment StartJul 2010
Primary CompletionJan 2012
TodayJul 2026
First PostedJun 22, 2010
Enrollment StartJul 1, 2010
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 16.0 years ago
Interventions
Cimziadrug
prefilled 200mg Cimzia syringe SC q 2 weeks
Placebodrug
prefilled saline syringe